StreetInsider.com News Articles

Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion

Thu, 22 Oct 2026 08:38:00 -0400

Liquid formulation of Niagen™ Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of the clinician-directed, prescription-only pharmaceutical-grade Niagen ™ At-Home Injection Kit, featuring the Company’s first ready-to-inject liquid formulation with Niagen™ (patented nicotinamide riboside, or

Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion

Thu, 22 Oct 2026 08:38:00 -0400

Liquid formulation of Niagen™ Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin

Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product

Tue, 20 Oct 2026 08:32:00 -0400

Following a customer-favorite limited release, Niagen NanoCloud™ debuts the Tru Niagen® Skincare category with a first-of-its-kind waterless, precision-dosed sachet technology that keeps Niagen’s benefits protected until activation

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by the Niagen® Skincare Innovation Lab. The inaugural product in this new category is

Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product

Tue, 20 Oct 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by the Niagen® Skincare Innovation Lab. The inaugural product in this new category is

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

Thu, 15 Oct 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2026. The company will report the financial results in a press release after the close of regular stock market trading hours on Wednesday, November 4, 2026.

Investor Conference Call:

A live webcast will be held on Wednesday, November 4,

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

Thu, 15 Oct 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2026. The company will report the financial results in a press release after the close of regular stock market trading hours on Wednesday, November 4, 2026.

Investor Conference Call:

A live webcast will be held on Wednesday, November 4,

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for

Thu, 08 Oct 2026 08:32:00 -0400

This award recognizes Dr. Shao’s dedication to advancing NAD+ research and scientific excellence responsibly within the dietary supplement industry

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Radicle Science and Council for Responsible Nutrition (CRN) honored Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, as the winner of the 2026 Annette Dickinson Trailblazer Award.

This press release features multimedia. View the full

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for

Thu, 08 Oct 2026 08:32:00 -0400

This award recognizes Dr. Shao’s dedication to advancing NAD+ research and scientific excellence responsibly within the dietary supplement industry

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Radicle Science and Council for Responsible Nutrition (CRN) honored Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, as the winner of the 2026 Annette Dickinson Trailblazer Award.

This press release features multimedia. View the full

Niagen Bioscience to Present at LD Micro 20th Annual Main Event

Tue, 06 Oct 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the 20th Annual LD Micro Main Event from Monday, October 19 to 21, 2026, in Los Angeles, CA.

Niagen Bioscience Chief Executive Officer, Robert Fried, will present on Wednesday, October 21st at 1:30 p.m. PT. To register for the Niagen Bioscience webcast, please visit www.ldmicroevents.com.

Chief Financial Officer, Ozan Pamir, will join Mr. Fried and be available for

Niagen Bioscience to Present at LD Micro 20th Annual Main Event

Tue, 06 Oct 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the 20th Annual LD Micro Main Event from Monday, October 19 to 21, 2026, in Los Angeles, CA.

Niagen Bioscience Chief Executive Officer, Robert Fried, will present on Wednesday, October 21st at 1:30 p.m. PT. To register for the Niagen Bioscience webcast, please visit www.ldmicroevents.com.

Chief Financial Officer, Ozan Pamir, will join Mr. Fried and be available for

Canaccord Reiterates Buy Rating on Niagen (NAGE)

Mon, 05 Oct 2026 06:58:06 -0400

Canaccord analyst Susan Anderson reiterated a Buy rating and $10.00 price target on Niagen (NASDAQ: NAGE).

The analyst commented: "We attended a dinner with Niagen Bioscience management, including CEO Rob Fried and CFO Ozan Pamir. Management highlighted its focus on healthy aging, consumer awareness, injectable NAD+, therapeutics, and skincare opportunities, reinforcing its strategy to evolve Niagen from a supplement company into a broader healthy aging platform. While NAGE has seen a slowdown in growth in FY26 due to competitive pressures from NMN, HK's Watson's, and lower ingredient sales, we expect a return to +DD consumer products growth in 2H26 and 2027

Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater

Thu, 01 Oct 2026 08:32:00 -0400

The campaign pairs a new perspective on aging with the Company’s 25+ years of quality and scientific leadership, including over 45 peer-reviewed published clinical studies on its flagship precursor ingredient Niagen® (patented nicotinamide riboside)

Slater leads a roster of more than 20 partners across sports, entertainment, and medicine, sharing their own Niagen® routines

Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater

Thu, 01 Oct 2026 08:32:00 -0400

Slater leads a roster of more than 20 partners across sports, entertainment, and medicine, sharing their own Niagen® routines

Niagen Bioscience signs planning deal with Mass General Brigham

Wed, 30 Sep 2026 08:34:04 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) has entered into a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for a large-scale clinical trial evaluating nicotinamide riboside (NR) supplementation in adults aged 50 and older, according to a company press release.

The proposed trial is designed as a multi-year, randomized, placebo-controlled study examining the short- and long-term effects of Niagen, the company's patented NR product, on major clinical and healthy aging outcomes. Outcomes under consideration include major morbidity and mortality, functional measures such as physical activity and cognition, wellness outcomes including energy and sleep, and biomarker-based measures related to biological

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

Wed, 30 Sep 2026 08:32:00 -0400

Proposed multi-year, randomized, placebo-controlled prevention trial would evaluate Niagen (patented nicotinamide riboside, or NR) supplementation across major clinical outcomes and healthy aging-related measures in adults aged 50 and older

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or NR) to date.

“This agreement reflects the

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

Wed, 30 Sep 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or NR) to date.

“This agreement reflects the

Niagen Bioscience: Study links CD38 enzyme to NAD+ decline in aging placental tissue

Mon, 21 Sep 2026 08:32:51 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) has highlighted an independent preclinical study published in Nature Communications that identifies the CD38 enzyme as a primary driver of NAD+ decline in aging placental tissue and finds that nicotinamide riboside (NR) improved pregnancy outcomes in aged mice.

The research, led by a team at Sichuan Agricultural University, measured NAD+ and related metabolites in human placental tissue from younger and older mothers. Older placentas contained lower levels of NAD+, NADH, and NADP+. Higher levels of those metabolites were associated with higher infant birth weight. Similar age-related declines were observed in mice and pigs, suggesting the pattern

Niagen Bioscience: Study links CD38 enzyme to NAD+ decline in aging placental tissue

Mon, 21 Sep 2026 08:32:51 -0400

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (

Mon, 21 Sep 2026 08:32:00 -0400

Preclinical study results showcase that CD38, an NAD-consuming enzyme more active with age and inflammation, leads to NAD+ depletion in placental tissue, while restoring NAD+ with the precursor NR improved placental, fetal, and offspring outcomes in aged mice

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (

Mon, 21 Sep 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary

Canaccord Reiterates Buy Rating on (NAGE)

Fri, 18 Sep 2026 06:43:16 -0400

Canaccord analyst Susan Anderson reiterated a Buy rating and $10.00 price target on (NASDAQ: NAGE).

The analyst commented: "Niagen Bioscience announced the engagement of Red Sky Partners and life sciences executive Martin Hendrix, Ph.D., to help advance its pharmaceutical strategy, including development of NB4168, its investigational small-molecule drug candidate targeting rare genetic diseases and aging-related disorders. The advisory appointments support Niagen’s long-term goal of translating its NAD+ expertise into therapies for rare and orphan diseases with significant unmet medical needs, with an initial focus on Ataxia Telangiectasia (A-T), a rare genetic disease with no FDA approved treatments currently available. The move

Niagen Bioscience adds advisors for drug development push

Thu, 17 Sep 2026 08:32:34 -0400

Niagen Bioscience, Inc. (NASDAQ: NAGE) said its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged life sciences advisory firm Red Sky Partners and independent advisor Martin Hendrix, Ph.D., to support the development of its investigational drug candidate NB4168 and broader corporate strategy.

Red Sky Partners advisors Pauline Jen Ryan and Christopher Kiritsy will focus on drug development, fundraising, strategic transactions, and commercialization. Ryan has nearly four decades of experience advising biotechnology companies and previously served as Senior Vice President of Corporate Development at ImmunoGen, where she helped raise close to $300 million. Kiritsy played a central role in building Kos Pharmaceuticals,

Niagen Bioscience adds advisors for drug development push

Thu, 17 Sep 2026 08:32:34 -0400

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Thu, 17 Sep 2026 08:32:00 -0400

Advisors bring biotechnology fundraising, drug development, and commercialization, as well as corporate strategy and M&A expertise to support the advancement of NB4168 and strategic corporate growth initiatives

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Thu, 17 Sep 2026 08:32:00 -0400

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug